LOS ANGELES--(BUSINESS WIRE)-- HemaCare Corporation (OTCBB:HEMA) announced today that the Company generated 2011 second quarter revenue of $4.2 million from continuing operations and a net loss of $252,000, or $(0.03)/share, including net income from discontinued operations of $180,000 compared to second quarter 2010 revenue from continuing operations of $3.9 million and net income of $223,000, or $.02/share, including net income of $843,000 from discontinued operations.
The Company generated 2011 year to date revenue of $8.1 million from continuing operations and a net loss of $642,000, or $(0.07)/share, including net income from discontinued operations of $285,000 compared to 2010 year to date revenue for continuing operations of $7.6 million and net income of $20,000, or $0.00/share, including net income of $1,595,000 from discontinued operations.
Commenting on the results, HemaCare’s Chief Executive Officer, Pete van der Wal, stated, “Our second quarter results include certain discontinued operations which we sold to American Red Cross in July of this year. We continue to believe that our remaining operations hold greater promise for profitable growth, and expect to judiciously employ part of the net cash gain of approximately $1.7 million from the July transaction to bolster our growth prospects.”
ABOUT HEMACARE CORPORATION
HemaCare Corporation is a blood services company serving healthcare providers and the scientific community for over 30 years. HemaCare and its subsidiary, Coral Blood Services, perform therapeutic apheresis services, provide human-derived biological products, and support the implementation of cellular therapy based trials with apheresis collections.
The company was founded in 1978 and is based in Van Nuys, California. It trades on the OTC Bulletin Board under the symbol “HEMA.”
This press release also contains “forward-looking statements” under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 (Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Statements herein that are not historical facts are forward-looking statements pursuant to the safe harbor provisions referenced above. You may also identify forward-looking statements by use of the words “anticipates,” “expects,” “intends,” “plans” and similar expressions. The forward-looking statements in this press release include statements that HemaCare expects its revenues from its cellular therapy and research products activities to increase in future periods and produce higher profit margins than those generated by the Company’s blood services segment. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified. Such risks and uncertainties include, without limitation, the following: lower than expected revenues from services the Company expects to provide to Dendreon Corporation; a reduction in operating margins occasioned by costs increasing more rapidly than market prices, the reduced demand for blood products, declining blood donations, the loss of customers or the inability to pass on cost increases due to increased competition, an increase in operating costs due to changes in industry regulations and standards, a decrease in reimbursement rates; our competitive position may decline due to the potential adverse effect from changes in the healthcare industry, including consolidations, which could affect access to customers, our inability to attract, retain and motivate management and other skilled employees, an increased emphasis by our competitors on customer service may diminish the advantages we enjoy from our service-focused operations, and our competitors’ not-for-profit status gives them advantages in acquiring customers; and the other risks and uncertainties discussed from time to time in the documents HemaCare files with the Securities and Exchange Commission. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlined in the forward-looking statements contained herein. The Company undertakes no obligation to update any of these forward-looking statements to reflect actual results or events or circumstances after the date hereof.
|Condensed Consolidated Data|
|Three Months Ended||Six Months Ended|
|June 30,||June 30,|
|Statements of Income:|
|General and administrative expenses||$||1,212,000||$||1,131,000||$||2,395,000||$||2,668,000|
|Gain from disposal of assets||$||197,000||$||0.00||$||197,000||$||0.00|
|Loss before income taxes and discontinued operations||($432,000||)||($610,000||)||($917,000||)||($1,565,000||)|
|Provision for income taxes||$||0.00||$||10,000||$||10,000||$||10,000|
|Net loss before discontinued operations||($432,000||)||($620,000||)||($927,000||)||($1,575,000||)|
|Income from discontinued operations, net of tax||$||180,000||$||843,000||$||285,000||$||1,595,000|
|Net (loss) income||($252,000||)||$||223,000||($642,000||)||$||20,000|
|Basic and diluted (loss) earnings per share||($0.03||)||$||0.02||($0.07||)||$||0.00|
|Weighted average shares outstanding – basic||9,712,948||10,049,148||9,712,948||10,049,339|
Weighted average shares outstanding – diluted
|Condensed Consolidated Balance Sheets||Unaudited|
|Cash and cash equivalents||$||1,683,000||$||1,638,000|
|Other current assets||5,152,000||5,170,000|
|Liabilities and Shareholders' Equity:|
|Total liabilities and shareholders' equity||$||9,715,000||$||9,843,000|
Pete van der Wal, 877-310-0717
Chief Executive Officer
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Stem Cells Surgery Health Hospitals Medical Devices Medical Supplies